

 **UDENYCA<sup>®</sup>**  
pegfilgrastim-cbqv  
Injection 6 mg/0.6 mL

**U**  
— get more with —  
**UDENYCA**



## UDENYCA can be your pegfilgrastim product of choice

*3 ADMINISTRATION  
OPTIONS*

*STABLE PRICING  
APPROACH*

*BROAD INSURANCE  
COVERAGE*

### IMPORTANT SAFETY INFORMATION

**UDENYCA (pegfilgrastim-cbqv) is contraindicated** in patients with a history of serious allergic reactions to pegfilgrastim products or filgrastim products. Reactions have included anaphylaxis.

**Splenic rupture:** Splenic rupture, including fatal cases, can occur following administration of pegfilgrastim products. Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture.

**Acute respiratory distress syndrome (ARDS):** Evaluate patients who develop fever, lung infiltrates, or respiratory distress. Discontinue UDENYCA in patients with ARDS.

**Serious allergic reactions, including anaphylaxis:** The majority of reported events occurred upon initial exposure. Allergic reactions, including anaphylaxis, can recur within days after the discontinuation of initial anti-allergic treatment. Permanently discontinue UDENYCA in patients with serious allergic reactions.

**Please see additional Important Safety Information throughout this brochure and full Prescribing Information.**



UDENYCA

### On-body injector

Automatic administration for your on-the-go patients

An option for patients who...

Live far away or depend on a caregiver for a ride

Are employed or have a busy schedule

Struggle with remembering to take medication

Prefer to rely on the device to deliver medication at the right time



UDENYCA

### Prefilled autoinjector

Simple-to-administer, at-home treatment for your independent patients; can also be used in the office in lieu of a prefilled syringe

An option for patients who...

Live far away or depend on a caregiver for a ride

Have concerns with wearing an on-body injector

Desire discretion and privacy around their treatment

Value autonomy over their treatment time\*

\*Should not be administered between 14 days before and 24 hours after cytotoxic chemotherapy.<sup>1</sup>



UDENYCA

### Prefilled syringe

For patients who prefer administration by their care team

An option for patients who...

Want to travel back to the provider's office the next day

Like the confidence of care team delivery

May be comforted by an extra office visit

Struggle staying compliant with at-home administration

#### IMPORTANT SAFETY INFORMATION (continued)

**Allergies to acrylics (UDENYCA ONBODY® only):** The on-body injector (OBI) for UDENYCA uses acrylic adhesive. For patients who have reactions to acrylic adhesives, use of this product may result in a significant reaction.

**Sickle cell disorders:** Severe and sometimes fatal crises have occurred in patients with sickle cell disorders. Discontinue UDENYCA if sickle cell crisis occurs.

**Glomerulonephritis:** The diagnoses were based upon azotemia, hematuria (microscopic and macroscopic), proteinuria, and renal biopsy. Generally, events resolved after dose reduction or discontinuation. Evaluate and consider dose-reduction or interruption of UDENYCA if causality is likely.

#### IMPORTANT SAFETY INFORMATION (continued)


**Leukocytosis:** White blood cell (WBC) counts of  $100 \times 10^9/L$  or greater have been observed in patients receiving pegfilgrastim products. Monitoring of complete blood count during UDENYCA therapy is recommended.

**Thrombocytopenia:** Thrombocytopenia has been reported in patients receiving pegfilgrastim products. Monitor platelet counts.

Please see additional Important Safety Information throughout this brochure and full Prescribing Information.



Fill guide, port, and indicator located on same side for **real-time view**



Needle retracts **automatically** after dose delivery

**Well-tolerated,**  
high-quality  
adhesive backing<sup>3\*</sup>

**Status light**  
indicates if device is  
working properly

\*Uses acrylic adhesive. For patients who have reactions to acrylic adhesives, use of this product may result in a significant reaction.<sup>1</sup>

## UDENYCA ONBODY may differ from what you are used to


Attribute	UDENYCA ONBODY <sup>1,2</sup>	Neulasta® (pegfilgrastim) Onpro <sup>®4,5</sup>
Injection time	<b>5 minutes</b> <b>90% faster</b> than Neulasta Onpro <sup>1,2,4,5</sup>	<b>45 minutes</b>
Injection modality	Needle is <b>inserted for only 5 minutes</b> at time of injection	Cannula remains inserted for ~27 hours plus injection time
Needle retraction	<b>Automatic</b> after delivery	No retraction after delivery
Fill process	Fill guide, port, and indicator on the same side for <b>real-time view</b>	Port and indicator on opposite sides of device
Adhesive	Large surface area with <b>well-tolerated adhesive</b> <sup>3</sup>	May use PodPals® extender to make adhesive surface larger

### IMPORTANT SAFETY INFORMATION (continued)

**Capillary leak syndrome:** Has been reported after granulocyte colony stimulating factor (G-CSF) administration, including pegfilgrastim products, and is characterized by hypotension, hypoalbuminemia, edema, and hemoconcentration. Episodes vary in frequency and severity and may be life-threatening if treatment is delayed. If symptoms develop, closely monitor and give standard symptomatic treatment, which may include a need for intensive care.

## Help prevent febrile neutropenia in 4 steps<sup>2</sup>

For complete application information and instructions on how to use UDENYCA ONBODY, please see the [Instructions for Use](#).




Prepare application site



Get the device ready



Apply the injector



Review important information with patient


Watch a video about the UDENYCA on-body injector



### IMPORTANT SAFETY INFORMATION (continued)

**Potential for tumor growth stimulatory effects on malignant cells:** The G-CSF receptor through which pegfilgrastim products and filgrastim products act has been found on tumor cell lines. The possibility that pegfilgrastim products act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, diseases for which pegfilgrastim products are not approved, cannot be excluded.

Please see additional Important Safety Information throughout this brochure and full [Prescribing Information](#).




## Simple administration in 2 clicks<sup>6</sup>

For complete application information and instructions on how to use the UDENYCA prefilled autoinjector, please see the [Instructions for Use](#).



### Before you begin

Hold the autoinjector with the clear cap facing up and pull to remove the cap.



1

Press against the skin and listen for the first click.



2

After the second click, hold in place and count to 5.

Watch a video about how your patients can use the UDENYCA autoinjector



**Dual coverage:** May be covered under pharmacy and medical benefits



Injects in less than 10 seconds<sup>3</sup>



Audio click and visual injection confirmations



Staff-friendly features for use in lieu of a prefilled syringe

### IMPORTANT SAFETY INFORMATION (continued)

**Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with breast or lung cancer:** MDS and AML have been associated with the use of pegfilgrastim products in conjunction with chemotherapy and/or radiotherapy in patients with breast or lung cancer. Monitor patients for signs and symptoms of MDS/AML in these settings.

### IMPORTANT SAFETY INFORMATION (continued)

**Potential device failures (UDENYCA<sup>®</sup> ONBODY only):** Missed or partial doses have been reported in patients receiving UDENYCA via the OBI due to the device not performing as intended. In the event of a missed or partial dose, patients may be at increased risk of events such as neutropenia, febrile neutropenia and/or infection than if the dose had been correctly delivered. Instruct patients using the OBI to notify their healthcare professional immediately to determine the need for a replacement dose of UDENYCA if they suspect that the device may not have performed as intended.

**Please see additional Important Safety Information throughout this brochure and full Prescribing Information.**

## UDENYCA PREFILLED SYRINGE

# Tried-and-true, in-office administration delivered by the care team\*

Suitable for patients who like the confidence of care team delivery



**UDENYCA**<sup>®</sup>  
pegfilgrastim-cbqv



Can be left at room temperature (68° F–77° F) for up to **48 hours** before being discarded<sup>2</sup>

Built-in needle **safety guard**

**Latex-free** needle cap

**Small 29-gauge, 1/2-inch needle**

\*May be prescribed for in-office or at-home use.

### IMPORTANT SAFETY INFORMATION (continued)

**Aortitis:** Has been reported in patients receiving pegfilgrastim products, occurring as early as the first week after start of therapy. Manifestations may include generalized signs and symptoms such as fever, abdominal pain, malaise, back pain, and increased inflammatory markers (eg, c-reactive protein and WBC count). Consider aortitis when signs and symptoms develop without known etiology. Discontinue UDENYCA if aortitis is suspected.

**Please see additional Important Safety Information throughout this brochure and full Prescribing Information.**



**More than 300,000 patients treated with UDENYCA prefilled syringe<sup>3†</sup>**

<sup>†</sup>January 2019 through August 2025.

Scan for more information about the **UDENYCA prefilled syringe.**



Actor portrayals

MORE PRICE STABILITY

## UDENYCA has historically been priced with stability in mind

### Why stability matters

**Providers** may find that it simplifies tasks like managing order sets, billing, coding, inventory, staff workflows, and contracts.

**Payers** may focus on securing the lowest prices but must also weigh long-term coverage needs in their planning.

### Accord's pricing strategy for UDENYCA aims to:

- Ensure consistency
- Provide as much stability as possible
- Enable predictability in a class that has historically seen pricing volatility

**Note:** Despite our efforts to price with stability in mind, the variability of pricing inputs (eg, sales, discounts, or other variables) may cause reimbursement to fluctuate from quarter to quarter.



**If you would like to review pricing for UDENYCA, please contact your Accord Key Account Manager or Key Account Director for more information.**

You can also request a representative by emailing [abimarketing@accord-healthcare.com](mailto:abimarketing@accord-healthcare.com).

### IMPORTANT SAFETY INFORMATION (continued)

**Nuclear imaging:** Increased hematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone imaging changes. Consider when interpreting bone imaging results.

## Billing and coding for UDENYCA

### Key details that may help facilitate appropriate billing and reimbursement

Coding	Description
HCPCS Q5111	Injection, pegfilgrastim-cbqv, biosimilar, (UDENYCA), 0.5 mg
CPT 96377	Application of on-body injector (includes cannula insertion) for timed subcutaneous injection
CPT 96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular

Billable Units	Description
12	Billable units for administration of one syringe/one autoinjector. When administering one syringe or one autoinjector, please use the JZ modifier to indicate zero drug amount discarded

NDC	Description
69448-025-63 (10 digit) 69448-0025-63 (11 digit)	6 mg/0.6 mL single-dose prefilled syringe
69448-026-63 (10 digit) 69448-0026-63 (11 digit)	6 mg/0.6 mL single-dose prefilled autoinjector
69448-027-63 (10 digit) 69448-0027-63 (11 digit)	6 mg/0.6 mL single-dose prefilled syringe and on-body injector

For questions regarding UDENYCA billing and coding, please call AccordCares at 1-844-483-3692 or visit [UDENYCA.com/hcp/AccordCares](https://UDENYCA.com/hcp/AccordCares).

The coding information contained herein is for informational purposes only and is not a guarantee of coverage or reimbursement for any product or service. This information is not intended to substitute for the physician's independent diagnosis or treatment of each patient.

**Please see additional Important Safety Information throughout this brochure and full Prescribing Information.**

MORE COVERAGE

## UDENYCA payer coverage remains broad and robust<sup>3</sup>



Broadest **pegfilgrastim biosimilar** coverage\*



~60% **parity** or preferred commercial coverage



> 75% **parity** or preferred Medicare Advantage coverage

### UDENYCA has favorable medical benefit coverage with major plans:

- Blue Shield of California†
- Cigna Commercial and Medicare Advantage
- UnitedHealthcare Commercial and Medicare Advantage

### UDENYCA autoinjector has broad pharmacy benefit coverage with major plans:

- Anthem Commercial
- Humana Medicare Advantage
- UnitedHealthcare Commercial



### Interactive Tool

Scan the QR code to review state-by-state coverage in the AccordCares Payer Coverage Tool.

\*For all insurance types inclusive of commercial and Medicare, as of July 2025.

†Other Blue Cross Blue Shield plans have moved UDENYCA from nonpreferred to advantaged. Please reach out to your Accord BioPharma Reimbursement Manager with any questions.

All presentations of UDENYCA may be covered under patient's medical benefit, and the autoinjector and prefilled syringe may be covered under both pharmacy and medical benefits.

## IMPORTANT SAFETY INFORMATION (continued)

The most common adverse reactions (≥5% difference in incidence compared to placebo) are bone pain and pain in extremity.

MORE FINANCIAL SUPPORT

## AccordCares co-pay and patient support services

**\$0** co-pay per UDENYCA treatment<sup>‡</sup>

<sup>‡</sup>For eligible patients.

AccordCares offers a co-pay program for eligible patients with commercial insurance that covers out-of-pocket expenses related to UDENYCA.

- Eligible patients may pay as little as **\$0 co-pay per UDENYCA treatment**
- Annual maximum benefit of \$15,000 for out-of-pocket expenses for UDENYCA, including co-pays or co-insurance. \$4,500 per claim and per unit (or per 6 mg /0.6 mL dose), up to 2 units for \$9,000

### Other offerings from AccordCares:



Benefits investigation



Prior authorization



Billing and coding information



Alternate funding referral

An AccordCares associate can be reached Monday through Friday, 8 AM to 8 PM ET, at:

Phone 1-844-483-3692

Fax 1-877-226-6370

Please see additional Important Safety Information throughout this brochure and full **Prescribing Information**.



## MEET Accord BioPharma

Accord BioPharma is a **United States-based company** focused on biosimilars and specialty pharmaceuticals that include oncology, immunology, and critical care therapies.

We're committed to providing treatments that are affordable, accessible, and tailored to the needs of your patients.



**Multiple FDA-approved**  
therapies



**Several oncology**  
**products**, including  
treatments for breast  
cancer and advanced  
prostate cancer



A robust pipeline  
spanning **immunology,**  
**neurology, and oncology**

## FASTEST GROWING

**Intas Pharmaceuticals**, the parent company of Accord, is the **fastest growing company** among the top 10 Indian pharmaceutical firms, with wide reach and dominance in several therapeutic areas, such as oncology, diabetes, and CNS.



# 85+

Accord also operates outside of the United States as **Accord Healthcare**, a trusted global biosimilar leader with over 2 decades of experience in the European Union and Asia, with **products sold in 85+ countries.**



Please see additional Important Safety Information throughout this brochure and full **Prescribing Information.**

*MORE CHOICE, STABILITY, AND ACCESS*

# U GET MORE WITH UDENYCA



- **3 administration options:**
  - **On-body injector:** Automatic administration for on-the-go patients
  - **Autoinjector:** Simple-to-administer, at-home treatment for independent patients
  - **Prefilled syringe:** For patients who prefer administration by their care team
- **Stable pricing approach:** UDENYCA is priced with stability in mind
- **Broad payer coverage:** UDENYCA pharmacy and medical benefit coverage is robust

Visit [UDENYCA.com/hcp](https://www.udenyca.com/hcp)  
for more information



## INDICATION

UDENYCA is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

### Limitation of Use

UDENYCA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

**To report SUSPECTED ADVERSE REACTIONS, contact Accord BioPharma Inc at 1-866-941-7875 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](https://www.fda.gov/medwatch).**

**Please see additional Important Safety Information throughout this brochure and full Prescribing Information.**

**References:** 1. UDENYCA (pegfilgrastim-cbqv) Prescribing Information. Accord BioPharma, Inc. 2. UDENYCA ONBODY HCP Instructions for Use. Accord BioPharma, Inc. 3. Data on file. Accord BioPharma, Inc.; 2025. 4. Neulasta® Onpro® Instructions for Use. Amgen. 5. Neulasta® (pegfilgrastim) Prescribing Information. Amgen 6. UDENYCA Autoinjector Instructions for Use. Accord BioPharma, Inc.